How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Researchers from Carnegie Mellon University's Human-Computer Interaction Institute have known that practice is essential for ...
On the morning of April 25, 2026, a tech founder watched his company's production database disappear. Not corrupted. Not partially overwritten. Gone, along with every backup, in nine seconds. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results